You are here: Home » Companies » News
Business Standard

Opto Circuits' arm launches new drug eluting stent

The launch follows approval from the Drug Controller General of India (DCGI) to sell and market the product in India

BS Reporter  |  Bangalore 

Opto Eurocor Healthcare Limited. (OEHL) a subsidiary of Bangalore-based medical devices maker Opto Circuits (India) Ltd.has launched its first Sirolimus Drug Eluting (DES), E-MAGIC® Plus.

The launch follows approval from the Drug Controller General of India (DCGI) to sell and market the product in India. With the launch of E-MAGIC® Plus, Opto Circuits has become one of the few global players to offer DES products with a choice of two drug coatings. The Sirolimus DES market is estimated to be worth Rs 800 crore annually in India.

E-MAGIC® Plus consists of a balloon-expandable intra coronary cobalt chromium pre-mounted on a custom balloon delivery system with a Sirolimus coating and a biodegradable polymer. The E-MAGIC® Plus releases a distinctive anti-rejection drug, Sirolimus (also known as Rapamycin), into the arterial wall. Sirolimus helps control excess growth of cells and allows the artery to heal. The stent has an extra edge with soft tip technology to provide smooth access to the lesion site ensuring minimal trauma to the vessel wall.   
A stent is a wire metal mesh tube that is used to prop open an occluded artery during an angioplasty. Some stents are coated with a drug, which is released into the wall of the artery to help minimize re-narrowing (restenosis) and the growth of scar tissues.

The DES market has two major drug categories: Sirolimus and Paclitaxel. Stents coated with Sirolimus & its derivatives are rapidly gaining market share thanks to the potent immunosuppressive nature of the drug and its comparative effectiveness in treating difficult lesions.

In India, Sirolimus-based angioplasty devices have a more than 90% market share.
Vinod Ramnani, Chairman & Managing Director, Opto Circuits (India) Ltd., “E-MAGIC® Plus has been developed indigenously in India and with the mark we can market and sell in India. The approval will also enable E-Magic Plus to be marketed in parts of Far East and parts of Middle East. We trust that E-MAGIC® Plus will offer better treatment options and significant therapeutic advantages for the patients.”

First Published: Mon, September 10 2012. 16:40 IST